• Spray-on skin to be commercialized

    Sheffield, U.K.-based Altrika set to produce a spray version of its Cryoskin donor skin cell product that can be applied in hospitals outside of a sterile surgical environment in order to reduce treatment time; the spray would be stored in individual doses so the right number of skin cells can be selected once the wound is assessed; the cells would then be thawed as the patient is being prepared

  • Anti-dengue mosquitoes to be released in Australia and Vietnam

    Some 100 million people in the tropics get dengue fever each year, and 40,000 are killed by it; the virus’s range is expanding, and last week France reported its first locally acquired cases; Australian scientists will release mosquitoes called Wolbachia that infect the disease-carrying Aedes mosquitoes, and makes them less able to carry the dengue virus; the release will take place in Australia and Vietnam

  • Sea floor organisms offer response to bioterrorism

    Two companies, with $30 million funding from the U.S. Defense Threat Reduction Agency, will search for new antibiotics at the bottom of the ocean that could be used to fight bioterrorism; the companies expect to find treatments for the bubonic plague, Yersinia pestis, and other bacterial infections that could be utilized by terror groups for an attack on the United States

  • A new dual vaccine protects against both smallpox and anthrax

    A new protective vaccine against both smallpox and anthrax, two agents of bioterrorism, shows promise in animal models; the new vaccine more quickly elicited immunity and was more effective than the licensed anthrax vaccine, BioThrax, in protecting mice and rabbits against anthrax

    • view counter

  • Georgia county tests drive-thru shot clinic

    Decatur County, Georgia, Health Department’s drive-thru flu shot clinic was held last Friday, and more than 250 people received their vaccination; the important thing, said Sherry Hutchins, Decatur of the County Health Department, is that “The clinic—- gives the health department a chance to test our ability to swiftly, efficiently dispense medicines during a mass-exposure event like a bioterrorism attack, a disaster or an influenza pandemic”

  • Virus related to smallpox rising sharply in Africa

    Thirty years after the eradication of smallpox, and the end of the mass smallpox vaccination campaign, rates of a related virus known as human monkeypox have increased dramatically in the rural Democratic Republic of Congo, with sporadic outbreaks in other African nations and even the United States

    • view counter

  • U.S. training developing world's docs to detect outbreaks earlier

    U.S.-funded program helps health workers in developing countries track disease and speed response to outbreaks; the CDC has established 35 programs since 1980, mostly in developing countries, with funding from several U.S. government agencies and nongovernmental organizations, and has 11 more in the works. Participants investigated 216 outbreaks in 2009

  • Vaccine work offers protection against weaponized plague bacteria

    Plague has been used as a weapon since the Middle Ages, when armies would hurl plague-infested bodies over castle walls; more recently, the United States, Japan, and the former Soviet Union have all studied the use of Y. pestis as a biological warfare agent; new research on the immune system’s response to plague could improve efforts to vaccinate the public against the world’s oldest form of biological warfare

  • New $186.6 million contract shows anthrax threat real

    In an indication that the threat of an anthrax outbreak as a result of bioterrorism remains a major priority for the Obama administration, Maryland-based Emergent BioSolutions received a contract valued at up to $186.6 million from the Department of Health and Human Services to develop a recombinant protective antigen anthrax vaccine, which is likely to produce a more rapid response to anthrax infection than existing vaccines

  • Work begins on the new U.S. premier BioLab

    DHS has released $40 million to allow work to begin on the U.S. new National Bio and Agro-Defense Facility, located on the campus of Kansas State University; the lab will replace the aging lab on Plum Island as the premier research center to combat the threat of naturally occurring animal diseases or agroterrorism; the Levl 4 BioLab will conduct research on human and animal disease to which there is yet no known cure

  • Researchers develop next generation antibiotics to combat drug-resistant "superbugs"

    Each year 90,000 people in the United States die of drug-resistant “superbugs” — bacteria like Staphylococcus aureus (MRSA), a deadly form of staph infection resistant to normal antibiotics; certain bacterial strains include enzymes which help the bacteria to inactivate antibiotics — and a team of researchers are working on turning this powerful mechanism against the bacteria itself

  • Docs: drug-resistant superbug is "time bomb" requiring global response

    Researchers warn that the spread of a drug-resistant bacterial gene could herald the end of antibiotics; the bleak prediction follows his research into a drug-resistant bacterial gene called NDM-1, or New Delhi metallo-beta-lactamase 1, which was first identified in India; the bug was found attached to E.coli bacteria, but the enzyme can easily jump from one bacterium to another and experts fear it will start attaching itself to more dangerous diseases causing them to become resistant to antibiotics

  • 395 medicines and Vaccines in development to fight infectious diseases

    More than 9.5 million people worldwide die each year from infectious diseases; in the United States, two million drug-resistant infections are reported each year, causing great suffering and costing the health system up to $34 billion a year; America’s biopharmaceutical research companies this year have 395 new medicines and vaccines in the pipeline to fight infectious diseases. All 395 are in later stages of development, meaning in clinical trials or under Food and Drug Administration (FDA) review

  • Passenger causing Thursday airport shutdown was at center of 2003 plague scare

    A passenger on a flight back from Saudi Arabia appeared to be carrying a suspicious canister — and TSA security checkers became even more alarmed when they realized that the passenger was the scientist who sparked a bioterrorism scare after he reported missing vials of plague samples in 2003; between 100 and 200 passengers were evacuated from four of the airport’s six concourses; airport roadways and a hotel near the airport’s international terminal were closed down

  • Pentagon shifts $1 billion from WMD-defense efforts to vaccine development

    The Obama administration has shifted more than $1 billion out of its nuclear, biological, and chemical defense programs to underwrite a new White House priority on vaccine development and production to combat disease pandemics; Defense Department projects under the budget-cutting ax include the development and acquisition of biological and chemical detection systems; gear to decontaminate skin and equipment after exposure; systems to coordinate military operations in a chem-bio environment; and protective clothing for military personnel entering toxic areas, the document indicates